OBJECTIVE:The main objective was to assess the impact of treatment with LMWH on the escalation of oxigen therapy or the need for invasive ventilation or mortality in patients admitted with SARS-CoV2 infection. 

METHODS:Independent, non-commercial. multicenter, randomized clinical trial of patients consecutive hospitalized for SARS-CoV2 infection. Patients are randomized to either experimental group, enoxaparin 1 mg/Kg/day or control group, enoxaparin 40mg/sc/day, for 14 days. All patients were followed up for 60 days. The primary efficacy event was the set of need for oxigen therapy escalation or invasive mechanical ventilation or mortality during admission. Secondary efficacy events were need for rescue medication and length of hospitalization. The hemorrhages were the primary safety variable.

RESULTS:We have analyzed 138 patients(median age: 55 years; IQR:15.6), 38% were women. The results on efficacity and safety events are summarized in Table 1.

CONCLUSIONS:No differences were found in the evolution of COVID between the two treatment groups for the profile of patients included in the trial. The increase in LMWH at an intermediate dose does not contribute benefits in a profile of patients with COVID who required hospitalization, but who had a favorable evolution in most of them. Financing: SEPAR 1128 and Neumosur Foundation.